trending Market Intelligence /marketintelligence/en/news-insights/trending/Nd1DlvLfNEd92Bgh4lTtUw2 content esgSubNav
In This List

Neuren Pharmaceuticals director to retire

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Neuren Pharmaceuticals director to retire

Neuren Pharmaceuticals Ltd. said Larry Glass would retire from the company's board, effective Dec. 31.

The company said Glass would continue to serve as the company's chief scientific officer.

Australia's Neuren Pharmaceuticals develops therapies for brain injury, neurodevelopment and neurodegenerative disorders.